DEAD/H Box 5 (DDX5) Augments E2F1-Induced Cell Death Independent of the Tumor Suppressor p53
Rinka Nakajima1, Yaxuan Zhou1, Mashiro Shirasawa1
1Department of Biomedical Sciences, School of Biological and Environmental Sciences, Kwansei Gakuin University, 1 Gakuen Uegahara, Sanda 669-1330, Hyogo, Japan.
Abstract:
In almost all cancers, the p53 pathway is disabled and cancer cells survive. Hence, it is crucially important to induce cell death independent of p53 in the treatment of cancers. The transcription factor E2F1 is controlled by binding of the tumor suppressor pRB, and induces apoptosis by activating the ARF gene, an upstream activator of p53, when deregulated from pRB by loss of pRB function. Deregulated E2F1 can also induce apoptosis, independent of p53, via other targets such as TAp73 and BIM. We searched for novel E2F1-interacting proteins and identified the RNA helicase DEAD/H box 5 (DDX5), which also functions as a transcriptional coactivator. In contrast to the reported growth-promoting roles of DDX5, we show that DDX5 suppresses cell growth and survival by augmentation of deregulated E2F1 activity. Over-expression of DDX5 enhanced E2F1 induction of tumor suppressor gene expression and cell death. Conversely, shRNA-mediated knockdown of DDX5 compromised both. Moreover, DDX5 modulated E2F1-mediated cell death independent of p53, for which DDX5 also functions as a coactivator. Since p53 function is disabled in almost all cancers, these results underscore the roles of DDX5 in E2F1-mediated induction of cell death, independent of p53, and represent novel aspects for the treatment of p53-disabled cancer cells.
Insights
The RNA helicase DDX5 enhances E2F1-induced cancer cell death, independent of the p53 pathway. This discovery offers new therapeutic strategies for p53-disabled cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Pathways
Background:
- The p53 pathway is frequently disabled in cancers, enabling cancer cell survival.
- Inducing cell death independent of p53 is crucial for effective cancer treatment.
- The transcription factor E2F1 can induce apoptosis, sometimes independent of p53.
Purpose of the Study:
- To identify novel proteins interacting with E2F1.
- To investigate the role of DDX5 in E2F1-mediated apoptosis, particularly in p53-deficient cancer cells.
Main Methods:
- Protein-protein interaction screening to identify E2F1 interactors.
- Overexpression and knockdown (shRNA) studies of DDX5.
- Analysis of E2F1-induced gene expression and apoptosis.
Main Results:
- DDX5 was identified as a novel E2F1-interacting protein and transcriptional coactivator.
- DDX5 suppresses cell growth and survival by augmenting deregulated E2F1 activity.
- DDX5 enhances E2F1-mediated apoptosis, including p53-independent cell death.
Conclusions:
- DDX5 acts as a coactivator for E2F1, promoting cell death.
- DDX5-mediated augmentation of E2F1 activity offers a novel therapeutic avenue for p53-disabled cancers.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
The Intrinsic Apoptotic Pathway
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
The Extrinsic Apoptotic Pathway


